Total Payments
$39,299
2024 Payments
$37,496
Companies
14
Transactions
64
Medicare Patients
1,406
Medicare Billing
$191,489
Payment Breakdown by Category
Other$25,499 (64.9%)
Consulting$6,785 (17.3%)
Travel$3,725 (9.5%)
Food & Beverage$3,289 (8.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $24,999 | 7 | 63.6% |
| Consulting Fee | $6,785 | 3 | 17.3% |
| Travel and Lodging | $3,725 | 15 | 9.5% |
| Food and Beverage | $3,289 | 38 | 8.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $500.00 | 1 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UROGEN PHARMA, INC. | $29,833 | 33 | $0 (2024) |
| Photocure Inc | $3,152 | 4 | $0 (2024) |
| Janssen Biotech, Inc. | $2,309 | 3 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $2,205 | 1 | $0 (2024) |
| KOELIS Inc. | $482.13 | 5 | $0 (2024) |
| Olympus Corporation of the Americas | $325.73 | 7 | $0 (2019) |
| Seagen Inc. | $254.44 | 2 | $0 (2022) |
| Edap Technomed Inc | $216.00 | 3 | $0 (2024) |
| IMMUNITYBIO, INC. | $136.37 | 1 | $0 (2024) |
| Exelixis Inc. | $125.00 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $37,496 | 44 | UROGEN PHARMA, INC. ($29,349) |
| 2023 | $608.85 | 4 | UroGen Pharma, Inc. ($308.68) |
| 2022 | $454.84 | 5 | UroGen Pharma, Inc. ($175.70) |
| 2021 | $315.32 | 2 | Seagen Inc. ($162.96) |
| 2019 | $325.73 | 7 | Olympus Corporation of the Americas ($325.73) |
| 2018 | $83.36 | 1 | Astellas Pharma US Inc ($83.36) |
| 2017 | $14.55 | 1 | BOSTON SCIENTIFIC CORPORATION ($14.55) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Honoraria | Cash or cash equivalent | $1,250.00 | General |
| Category: UROTHELIAL CANCER | ||||||
| 12/05/2024 | Edap Technomed Inc | — | Food and Beverage | Cash or cash equivalent | $72.00 | General |
| 12/05/2024 | Edap Technomed Inc | — | Food and Beverage | Cash or cash equivalent | $72.00 | General |
| 12/05/2024 | Edap Technomed Inc | — | Food and Beverage | Cash or cash equivalent | $72.00 | General |
| 12/05/2024 | KOELIS Inc. | Trinity (Device) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: Urology | ||||||
| 12/04/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $177.48 | General |
| Category: UROTHELIAL CANCER | ||||||
| 12/04/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $32.51 | General |
| Category: UROTHELIAL CANCER | ||||||
| 11/19/2024 | Photocure Inc | CYSVIEW (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Honoraria | Cash or cash equivalent | $3,437.50 | General |
| Category: UROTHELIAL CANCER | ||||||
| 11/13/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Travel and Lodging | In-kind items and services | $291.85 | General |
| Category: UROTHELIAL CANCER | ||||||
| 11/04/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Honoraria | Cash or cash equivalent | $5,312.00 | General |
| Category: UROTHELIAL CANCER | ||||||
| 11/04/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Consulting Fee | Cash or cash equivalent | $2,205.00 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Travel and Lodging | In-kind items and services | $550.95 | General |
| Category: UROTHELIAL CANCER | ||||||
| 11/04/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Travel and Lodging | In-kind items and services | $222.07 | General |
| Category: UROTHELIAL CANCER | ||||||
| 11/04/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Travel and Lodging | Cash or cash equivalent | $187.84 | General |
| Category: UROTHELIAL CANCER | ||||||
| 11/04/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | Cash or cash equivalent | $80.66 | General |
| Category: UROTHELIAL CANCER | ||||||
| 11/04/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $69.11 | General |
| Category: UROTHELIAL CANCER | ||||||
| 10/24/2024 | Janssen Biotech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,180.00 | General |
| 10/24/2024 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $79.71 | General |
| 10/24/2024 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $48.87 | General |
| 10/21/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Honoraria | Cash or cash equivalent | $5,312.00 | General |
| Category: UROTHELIAL CANCER | ||||||
| 10/21/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Travel and Lodging | In-kind items and services | $721.96 | General |
| Category: UROTHELIAL CANCER | ||||||
| 10/21/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Travel and Lodging | In-kind items and services | $299.15 | General |
| Category: UROTHELIAL CANCER | ||||||
| 10/21/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Travel and Lodging | Cash or cash equivalent | $176.82 | General |
| Category: UROTHELIAL CANCER | ||||||
| 10/21/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $136.43 | General |
| Category: UROTHELIAL CANCER | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 319 | 370 | $295,405 | $24,192 |
| 2022 | 18 | 481 | 634 | $603,749 | $70,560 |
| 2021 | 15 | 458 | 572 | $630,327 | $81,521 |
| 2020 | 9 | 148 | 158 | $108,607 | $15,215 |
Total Patients
1,406
Total Services
1,734
Medicare Billing
$191,489
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 90 | 104 | $45,667 | $6,911 | 15.1% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2023 | 99 | 122 | $119,087 | $6,890 | 5.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 19 | 19 | $14,626 | $2,539 | 17.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 22 | 22 | $12,782 | $1,874 | 14.7% |
| 52204 | Biopsy of bladder using an endoscope | Facility | 2023 | 21 | 22 | $49,632 | $1,837 | 3.7% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2023 | 13 | 18 | $39,600 | $1,646 | 4.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 11 | 12 | $6,743 | $1,294 | 19.2% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2023 | 29 | 36 | $3,458 | $662.40 | 19.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 15 | 15 | $3,810 | $539.11 | 14.1% |
| 51595 | Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small or large bowel with creation of urinary opening | Facility | 2022 | 12 | 12 | $111,534 | $19,477 | 17.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 107 | 148 | $55,796 | $10,051 | 18.0% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2022 | 75 | 130 | $126,490 | $7,275 | 5.8% |
| 55840 | Removal of prostate | Facility | 2022 | 12 | 12 | $55,420 | $5,642 | 10.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 34 | 34 | $24,742 | $4,364 | 17.6% |
| 52240 | Destruction and/or removal of large growth of bladder using an endoscope | Facility | 2022 | 14 | 14 | $22,867 | $3,797 | 16.6% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2022 | 19 | 33 | $73,055 | $3,346 | 4.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 35 | 35 | $20,335 | $3,324 | 16.3% |
| 52235 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | Facility | 2022 | 13 | 15 | $18,097 | $2,890 | 16.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 19 | 22 | $11,121 | $2,300 | 20.7% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 21 | 21 | $8,736 | $1,561 | 17.9% |
| 52204 | Biopsy of bladder using an endoscope | Facility | 2022 | 16 | 17 | $38,451 | $1,333 | 3.5% |
| 55700 | Biopsy of prostate gland | Facility | 2022 | 16 | 16 | $14,224 | $1,248 | 8.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 20 | $5,940 | $1,062 | 17.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 17 | 36 | $5,868 | $992.79 | 16.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 19 | 20 | $5,072 | $953.32 | 18.8% |
About Dr. Vignesh Packiam, M.D
Dr. Vignesh Packiam, M.D is a Urology healthcare provider based in Iowa City, Iowa. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/06/2012. The National Provider Identifier (NPI) number assigned to this provider is 1366707242.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vignesh Packiam, M.D has received a total of $39,299 in payments from pharmaceutical and medical device companies, with $37,496 received in 2024. These payments were reported across 64 transactions from 14 companies. The most common payment nature is "Honoraria" ($24,999).
As a Medicare-enrolled provider, Packiam has provided services to 1,406 Medicare beneficiaries, totaling 1,734 services with total Medicare billing of $191,489. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Other Specialties Medical Oncology, Urology
- Location Iowa City, IA
- Active Since 07/06/2012
- Last Updated 09/16/2020
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1366707242
Products in Payments
- JELMYTO (Drug) $29,619
- CYSVIEW (Drug) $2,999
- ADSTILADRIN (Biological) $2,205
- Trinity (Device) $482.13
- Olympus Cystoscopes (Device) $325.73
- PADCEV (Biological) $162.96
- Cysview (Drug) $152.36
- ANKTIVA (Drug) $136.37
- Cabometyx (Drug) $125.00
- HOPKINS (Device) $99.97
- ORGOVYX (Drug) $62.66
- GREENLIGHT (Device) $14.55
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Iowa City
Dr. Michael Odonnell, Md, MD
Urology — Payments: $79,346
Urology $79,346
Katherine Cotter, Md, MD
Urology — Payments: $75,684
Urology $75,684
Bradley Erickson, M.d, M.D
Urology — Payments: $63,949
Urology $63,949
Alexandria Hertz
Urology — Payments: $50,787
Urology $50,787
Dr. Hing Hung Lai, Md, MD
Urology — Payments: $22,467
Urology $22,467
Dr. Christopher Cooper, Md, MD
Urology — Payments: $10,035
Urology $10,035